SitesBLAST
Comparing WP_079648661.1 NCBI__GCF_900167915.1:WP_079648661.1 to proteins with known functional sites using BLASTp with E ≤ 0.001.
Or try Sites on a Tree, PaperBLAST, Conserved Domains, or compare to all protein structures
Found 20 (the maximum) hits to proteins with known functional sites (download)
6umcB Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 6umcB
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-N-{5-[(3R)-3-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}oxy)pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), E189 (= E107), Y258 (= Y178)
6ujgA Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 6ujgA
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding N-{5-[(3S)-3-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]amino}pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), Y258 (= Y178)
5wj6A Crystal structure of glutaminasE C in complex with inhibitor 2-phenyl- n-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}amino) piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide (upgl-00004) (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 5wj6A
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-N-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}amino)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: R181 (≠ A99), K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), N188 (≠ L106), E189 (= E107), Y258 (= Y178)
5i94A Crystal structure of human glutaminasE C in complex with the inhibitor upgl-00019 (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 5i94A
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-N-{5-[4-({5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}oxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: R181 (≠ A99), K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), Y258 (= Y178)
6umfA Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6umfA
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding N-(5-{[1-(5-amino-1,3,4-thiadiazol-2-yl)piperidin-4-yl]oxy}-1,3,4-thiadiazol-2-yl)-2-phenylacetamide: L185 (≠ I103), L187 (≠ Q105), Y258 (= Y178)
6uljA Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6uljA
6ulaA Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6ulaA
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-cyclopropyl-N-{5-[4-({5-[(cyclopropylacetyl)amino]-1,3,4-thiadiazol-2-yl}oxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), N188 (≠ L106), Y258 (= Y178)
6ukbA Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6ukbA
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding N-[5-(4-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]oxy}piperidin-1-yl)-1,3,4-thiadiazol-2-yl]acetamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), Y258 (= Y178)
6ujmA Crystal structure of human gac in complex with inhibitor upgl00013
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6ujmA
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding N-{5-[(3R)-3-{[5-(acetylamino)-1,3,4-thiadiazol-2-yl]amino}pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl}acetamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), Y258 (= Y178)
8jubA Crystal structure of glutaminasE C in complex with compound 27 (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 76:370/401 of 8jubA
5fi7A Crystal structure of human gac in complex with inhibitor upgl_00015: 2-phenyl-~{n}-[5-[(3~{s})-3-[[5-(2-phenylethanoylamino)-1,3,4- thiadiazol-2-yl]oxy]pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]ethanamide (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 5fi7A
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-~{N}-[5-[(3~{S})-3-[[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]oxy]pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]ethanamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), E189 (= E107), Y258 (= Y178)
5fi6A Crystal structure of human gac in complex with inhibitor upgl_00011: 2-phenyl-~{n}-[5-[[(3~{s})-1-[5-(2-phenylethanoylamino)-1,3,4- thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2- yl]ethanamide (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 5fi6A
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-~{N}-[5-[[(3~{S})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide: R181 (≠ A99), F182 (= F100), K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), N188 (≠ L106), E189 (= E107), Y258 (= Y178)
5fi2A Crystal structure of human gac in complex with inhibitor upgl_00009: 2-phenyl-~{n}-[5-[[(3~{r})-1-[5-(2-phenylethanoylamino)-1,3,4- thiadiazol- 2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2- yl]ethanamide (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/410 of 5fi2A
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-~{N}-[5-[[(3~{R})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide: K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), Y258 (= Y178)
6umdB Crystal structure of human gac in complex with inhibitor upgl00012
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6umdB
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-(pyridin-3-yl)-N-(5-{4-[(5-{[(pyridin-3-yl)acetyl]amino}-1,3,4-thiadiazol-2-yl)amino]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)acetamide: R181 (≠ A99), K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), N188 (≠ L106), E189 (= E107), Y258 (= Y178)
6ul9B Crystal structure of human gac in complex with inhibitor upgl00023
37% identity, 92% coverage: 5:296/318 of query aligns to 84:378/409 of 6ul9B
- active site: S150 (= S69), K153 (= K72), Y278 (= Y196), Y330 (= Y248), V348 (= V266)
- binding 2-phenyl-N-{5-[(1-{5-[(phenylacetyl)amino]-1,3,4-thiadiazol-2-yl}azetidin-3-yl)oxy]-1,3,4-thiadiazol-2-yl}acetamide: R181 (≠ A99), K184 (≠ S102), L185 (≠ I103), F186 (≠ V104), L187 (≠ Q105), N188 (≠ L106), E189 (= E107), Y258 (= Y178)
8jueA Crystal structure of glutaminasE C in complex with compound 11 (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 77:371/401 of 8jueA
6loxA Crystal structure of human glutaminase with macrocyclic inhibitor (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 82:376/407 of 6loxA
- active site: S148 (= S69), K151 (= K72), Y276 (= Y196), Y328 (= Y248), V346 (= V266)
- binding (E)-15,22-Dioxa-4,11-diaza-5(2,5)-thiadiazola-10(3,6)-pyridazina-1,14(1,3)-dibenzenacyclodocosaphan-18-ene-3,12-dione: K182 (≠ S102), L183 (≠ I103), F184 (≠ V104), L185 (≠ Q105), N186 (≠ L106), Y256 (= Y178)
5w2jB Crystal structure of dimeric form of mouse glutaminasE C (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 85:379/411 of 5w2jB
Sites not aligning to the query:
O94925 Glutaminase kidney isoform, mitochondrial; GLS; K-glutaminase; L-glutamine amidohydrolase; EC 3.5.1.2 from Homo sapiens (Human) (see 5 papers)
37% identity, 92% coverage: 5:296/318 of query aligns to 220:514/669 of O94925
- Y249 (= Y32) mutation to A: Loss of enzyme activity.
- S286 (= S69) binding substrate; mutation to A: Loss of enzyme activity.
- K289 (= K72) mutation to A: Loss of enzyme activity.
- P313 (= P95) to L: in GDPAG; loss of enzyme activity; dbSNP:rs1558973667
- F318 (= F100) mutation to Y: No effect on catalytic activity. Loss of inhibition by BPTES; when associated with S-322.
- L321 (≠ I103) mutation to A: Decreased enzyme activity.
- F322 (≠ V104) mutation to S: No effect on catalytic activity. Loss of inhibition by BPTES; when associated with Y-318.
- L323 (≠ Q105) mutation to A: Decreased enzyme activity.
- N335 (= N119) binding substrate
- E381 (= E165) binding substrate
- N388 (= N172) binding substrate
- Y394 (= Y178) mutation to A: Decreased enzyme activity.; mutation to L: No effect on catalytic activity. Loss of inhibition by BPTES.
- Y414 (= Y196) binding substrate
- Y466 (= Y248) binding substrate; mutation to A: Loss of enzyme activity.
- S482 (= S264) to C: in CASGID; increased enzyme activity; dbSNP:rs1558986214
- V484 (= V266) binding substrate
8gwrB Near full length kidney type glutaminase in complex with 2,2-dimethyl- 2,3-dihydrobenzo[a] phenanthridin-4(1h)-one (ddp) (see paper)
37% identity, 92% coverage: 5:296/318 of query aligns to 77:371/501 of 8gwrB
Sites not aligning to the query:
Query Sequence
>WP_079648661.1 NCBI__GCF_900167915.1:WP_079648661.1
MPVTVAPDLQAIVDRIAAEMAGREERGKVADYIPGLARVDPKHFGIAVATHDGRMFAAGD
ADAAFSIQSVSKVFALTIALGKVGDALWKRVGREPSGNAFNSIVQLEAEQGIPRNPFINA
GAIVVSDVVLAGHAPKEAIGEILRFVRDLAGDDGIVIDDEVAQGEADTGFRNAALANYMR
SFGNIHHPVDQVLGVYFHQCALAMSCRQLARAGRFLMHEGQHPDTGFNIVSPMRARRINA
LMMLCGHYDGSGEFAFRVGIPGKSGVGGGILCVVPGIASIAVWSPGLNERGNSTLGSLAL
ERLAAATGWSVFNQREPG
Or try a new SitesBLAST search
SitesBLAST's Database
SitesBLAST's database includes
(1) SwissProt
entries with experimentally-supported functional features;
and (2) protein structures with bound ligands, from the
BioLip database.
by Morgan Price,
Arkin group
Lawrence Berkeley National Laboratory